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ABSTRACT
Objectives: Staphylococcus aureus is often linked with human infection. Clindamycin is one of the key substitute antimicrobial agents in the treatment 
of S. aureus, especially in methicillin-resistant S. aureus (MRSA) infections. Inducible macrolide-lincosamide-streptogramin B (iMLS B) resistance 
is a crucial factor in antimicrobial susceptibility testing. The intention of the research was to identify S. aureus from distinct clinical specimens and 
investigate the prevalence of inducible clindamycin resistance among them and also study their association with MRSA.
Methods: A descriptive cross-sectional study was accomplished in the Dept. of Microbiology CMC-TH, Nepal from January 2018 to December 2020 
with 525 non-repeated S. aureus obtained from a different clinical specimen. Antibiotic susceptibility test was performed by Kirby–Bauer disc diffusion 
method. MRSA was detected using cefoxitin (30 µg) and results were interpreted as stated by CLSI. “D-Test” was done by applying erythromycin 
(15 µg) and clindamycin (2 µg) as per CLSI guidelines. Data were analyzed using SPSS IBM version 20.
Results: Among 525 isolates, there were 315 (60.00%) MRSA. Results of D test analysis showed that 280 (53.33%) were MLSB sensitive while 245 
(46.67%) were MLSB resistant; where 80 (15.24%) iMLSB with D zone, 100 (19.05%) constitutive MLSB (cMLSB) phenotype, and 65 (12.38%) 
MS phenotype. Of a total of 80 iMLSB, a significant proportion of 64 (80.00%) was MRSA (p<0.001). All the isolates were sensitive to vancomycin, 
teicoplanin, and linezolid. The prevalence of both iMLSB and cMLSB was high among MRSA.
Conclusion: In this study, cMLSB phenotype was predominant (19.05%) followed by iMLSB phenotype (15.25%) and then MS phenotype (12.38%). 
Inducible iMLS B phenotypes, as well as cMLSB, are higher among MRSA. It is advisable to include “D-Test” as a part of regular antibiotic susceptibility 
testing to detect iMLSB resistance among S. aureus.
Keywords: Staphylococcus aureus, Methicillin-resistant Staphylococcus aureus, Clindamycin resistance, Erythromycin resistance, D-Test, Inducible 
macrolide-lincosamide-streptogramin B, Constitutive MLSB, MS phenotype.
INTRODUCTION
Staphylococci were first identified by Sir Alexander Ogston in 
1880, in pus from a surgical abscess in a knee joint; later in 1884, 
Freidrich Jukius Rosenbach distinguishes Staphylococcus aureus 
from Staphylococcus epidermidis [1]. S. aureus is small, ovoid, Gram-
positive cocci found typically in grape-like clusters or may occur 
in pairs or singly [2]. It commonly colonizes the skin and noses 
of healthful individuals. However harmless at these sites, it may 
get into the body through a crack in the epidermis, for example, 
erosion, scratch, lesion, surgical procedure, and Foley catheters and 
give rise to infections [3]. It is accountable for extensive infections 
including bacterial skin infections, food poisoning, and osteomyelitis; 
moreover, it is a foremost source of nosocomial infection, extending 
out of minor skin diseases to a disastrous state such as post-operative 
wound infection, nosocomial pneumonia, sepsis, and bacterial 
endocarditis [4,5].
S. aureus infections generally respond to β-lactam and related 
classes of antibiotics such as macrolide-lincosamide-streptogramin 
(MLS) group. Nevertheless, because of the evolution of methicillin 
resistance out of S. aureus isolates, the therapeutics of such infections 
have become difficult [6]. The rise of methicillin-resistant S. aureus 
(MRSA) among staphylococci is inflation trouble and clindamycin is 
considered as one of the powerful other agents accessible to address 
this issue [7]. One of the most key reasons for MRSA evolution is 
redundant and wide ranging antibiotic overuse for less severe 
infections. Unluckily these MRSA isolates which are susceptible 
only to glycopeptides antibiotics such as vancomycin are becoming 
multidrug resistant (MDR) [8]. The rise in the number of MDR 
strains has led to a renewed curiosity in the utilization of macrolide 
(e.g., erythromycin)-lincosamide (e.g., clindamycin)-streptogramin 
B (e.g., quinupristin/dalfopristin) (collectively called as MLSB 
family) antibiotics to treat S. aureus infections with clindamycin 
being the favorable agent because of its superb pharmacokinetic 
properties [9].
Staphylococcal strains resistant to MLSB antibiotics have escalated 
in number after the extensive use of these antibiotics for treating 
serious staphylococcal infections [10]. The most usual process for 
such resistance is target site modification mediated by erm genes, 
which can be demonstrated either constitutively (cMLSB phenotype) 
or inducible (iMLSB phenotype). The erm genes code for methylase 
enzyme which methylates and alters the target site of MLSB antibiotics, 
that is, the 23S ribosomal RNA [11]. Active efflux pump encoded by 
msr A gene (MS phenotype) is another process of resistance [12]. 
S. aureus with constitutive resistance show resistance to erythromycin 
and clindamycin on in vitro testing, whereas isolates with inducible 
resistance show resistance to erythromycin but seem susceptible to 
clindamycin on disc diffusion test. Inducible clindamycin resistance 
in staphylococci can be detected by D test [13]. It is advocated that 
an accurate proportion of clindamycin resistance is being misjudged, 
especially for laboratories where testing for inducible resistance is not 
routinely done. For this reason, it is recommended that microbiology 
laboratories must accomplish the D-zone test on all staphylococcal 
strains that are erythromycin resistant and clindamycin sensitive, 
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before communicating clindamycin sensitive, to ascertain those strains 
that perhaps resistant in the course of treatment [14]. Failure to point 
out iMLSB resistance may accelerate the clinical failure of clindamycin 
treatment [15].
The incidence of clindamycin resistance varies from place to place and 
therefore a local data are important to guide empirical treatment [16]. 
In Nepal, few reports on the prevalence of inducible clindamycin 
resistance among S. aureus have been published [17,18]. Data 
describing the prevalence of clindamycin resistance among clinical 
isolates of S. aureus and MRSA are lacking in our geographic area. Thus, 
the present study was accomplished to determine the prevalence of 
inducible clindamycin resistance among S. aureus isolates and also to 
study their association with MRSA in our set up.
METHODS
The study was conducted in the Department of Microbiology CMC-
TH, Nepal, from January 2018 to December 2020 with 525 non-
repetitive S. aureus isolated from distinct clinical specimens. Antibiotic 
susceptibility test was performed by Kirby–Bauer disc diffusion 
method [19,20]. Based on the hospital antibiotic policy, the following 
antibiotics were used, namely, amikacin (30 µg), amoxiclav (30 µg) 
(amoxicillin/clavulanic acid 20/10 µg), cefoxitin (30 µg), ceftriaxone 
(30 µg), ciprofloxacin (5 µg), clindamycin (2 µg), cotrimoxazole (25 µg) 
(trimethoprim/sulfamethoxazole 1.25/3.75 µg), erythromycin (15 µg), 
gentamicin (10 µg), cloxacillin (5 µg), linezolid (30 µg), penicillin 
(10 units), piperacillin/tazobactam (100/10 µg), tigecycline (15 µg), 
tetracycline (30 µg), teicoplanin (30 µg), and vancomycin (30 µg). 
Sensitivity testing of vancomycin and teicoplanin was done by the 
minimum inhibitory concentration method. All antimicrobial drugs 
were obtained from HiMedia Laboratories, India. Screening of MRSA 
was done using cefoxitin (30 µg). If the cefoxitin (30 µg) zone of 
inhibition was less than 21 mm, it was reported as MRSA (Fig. 1) [19].
Inducible clindamycin resistance was detected using erythromycin (15 µg) 
and clindamycin (2 µg) as per CLSI guideline [20]. Three different types of 
the phenotype were appreciated and interpreted. Inducible MLSB (iMLSB) 
phenotype: Staphylococcal isolates showing resistance to erythromycin 
while being sensitive to clindamycin and giving a D-shaped zone of inhibition 
around clindamycin with flattening toward erythromycin disc. Constitutive 
MLSB (cMLSB) phenotype: Those staphylococcal isolates, which showed 
resistance to both erythromycin and clindamycin with the circular shape 
of the zone of inhibition, if any around clindamycin. MS phenotype: Isolates 
exhibiting resistance to erythromycin and sensitivity to clindamycin and 
giving a circular zone of inhibition around clindamycin (Fig. 2).
To verify that the susceptibility result is accurate, control strain of 
S. aureus American type culture collection (ATCC) 25293 was streaked 
on the prepared media plates and observed for significant growth. 
Control strains of E. coli (ATCC 25922), S. aureus (ATCC 25923), and 
P. aeruginosa (ATCC 27853) were used for the standardization of the 
Kirby–Bauer test and also for the correct interpretation of the zone of 
inhibition. For MRSA test standardization, S. aureus strains ATCC 25923 
were used as negative and ATCC 43300 were used as positive controls. 
Qualities of each agar plate were tested by incubating one plate of each 
batch on the incubator overnight without inoculating. The collected 
data were summarized, presented, and analyzed using the software 
SPSS version 20 (Chicago, USA). Qualitative data were summarized 
as frequency and percentages. p<0.05 was considered statistically 
significant. Ethical approval was taken from Chitwan Medical College 
(CMC) – Institutional Review Committee. Informed consent was taken 
from the patient before their inclusion in the research.
RESULTS
Demographic distribution and identification of bacterial isolates
A total of 525 non-repetitive S. aureus were collected from the different 
specimens. Among them, 420 (80.00%) were from pus, 42 (8.00%) from 
blood, 26 (4.95%) from sputum, 21 (4.00%) from urine, and 16 (3.05 %) 
from body fluid and tissue, respectively. Isolation frequency of S. aureus 
was 273 (52.00%) and 252 (48.00%) among males and females, 
respectively. S. aureus was dominant in IPD patient 315 (60.00%) than 
OPD patient 210 (40.00%). Among IPD patient, the growth of S. aureus 
was predominant in surgical ward 157 (29.90%) followed by medicine 
ward 82 (15.62%), orthopedic ward 65 (12.38%), medical/pediatric/
neonatal ICU and CCU 63 (12.00%), pediatric ward 53 (10.10%), ENT 
ward 42 (8.00%), gynecology ward 42 (8.00%), and tropical ward 21 
(4.00%). Out of 525 S. aureus, 315 (60.00%) were MRSA. MRSA isolates 
were isolated more from pus 257 (48.95%) as compared to other 
samples. The distribution of MRSA was found to be dominant in IPD 
patients 195 (37.14%) compared to 120 (22.86%) among OPD patients. 
Results of D test analysis showed that out of 525 S. aureus, 80 (15.24%) 
showed a D zone; where 280 (53.33%) were MLSB sensitive while 
245 (46.67%) were MLSB resistant. In this study, cMLSB phenotype 
was predominant 100 (19.05%) followed by the iMLSB phenotype 80 
(15.25%) and then MS phenotype 65 (12.38%), as shown in Fig. 3.
iMLSB phenotype as well as cMLSB was higher among MRSA 64 
(20.32%) and 79 (25.08%) as compared to MSSA 16 (7.62%) and 21 
(10.00%), respectively (Chi-square test, p<0.001), as expressed in 
Table 1.
Fig. 1: Detection of methicillin-resistant Staphylococcus 
aureus using cefoxitin disk. (a) Methicillin-resistant S. aureus. 
(b) Methicillin-sensitive S. aureus
ba
Fig. 2: Different MLSB phenotype. (a) iMLSB phenotype. (b) cMLSB phenotype. (c) MS phenotype
cba
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Antibiotic sensitivity profile
β-lactams, sulfonamides, quinolones, aminoglycosides, tetracycline, 
glycopeptides, macrolide, lincosamide, and oxazolidinones groups 
of antibiotics were tested against S. aureus isolates. All the isolates 
(100%) were sensitive to vancomycin, teicoplanin, and linezolid. 
Among antibiotics of β-lactam class, penicillin was least effective 
with only 14.29% sensitivity. Cloxacillin showed 42.86%, cefoxitin 
showed 41.41%, and amoxicillin/clavulanic acid showed 40.00% 
sensitivity. Other antibiotics of the same class showed a sensitivity rate 
of less than 40%. Another antibiotic with a higher sensitivity rate was 
amikacin 88.00%. Gentamicin, being from the same class of antibiotics 
(aminoglycosides), had 48.95% sensitivity. Ciprofloxacin was the least 
effective with a sensitivity rate of 31.05%. Cotrimoxazole was 58.86% 
sensitive. Erythromycin and clindamycin both had more than 50% 
sensitivity rate, that is, 52.95% and 66.10%, respectively. Antibiotic 
from the group tetracycline was also effective. Tetracycline had 55.05% 
sensitivity while tigecycline had 44.95% sensitivity. Detail summary of 
the susceptibility pattern of S. aureus isolates is shown in Table 2.
DISCUSSION
Screening for antimicrobial susceptibility among the clinical bacterial 
isolates is important for the best result of the treatment. In our 
study, of 525 isolates of S. aureus, 80.00% were from the pus sample, 
which signifies their leading role in abscess formation. Antimicrobial 
resistance has been observed as one of the supreme microbial threats 
of this century [21]. One of the crucial issues while treating infection 
caused by S. aureus is due to the multidrug resistance plus the 
emergence of methicillin resistance [22]. Clindamycin is commonly 
used for the treatment of skin and soft-tissue infections caused by 
S. aureus. However, S. aureus with inducible clindamycin resistance is 
increasing day by day, form such mutant’s constitutive resistance can 
arise spontaneously during clindamycin therapy [23]. Therefore, all the 
clinical isolates of S. aureus must be checked for inducible resistance 
(D-test) before clindamycin is reported as susceptible and to prevent 
therapeutic failure [24]. In the present study, the overall prevalence of 
inducible clindamycin resistance (iMLSB) among the clinical isolates 
of S. aureus was 15.24% which is near to the report of Singh et al., 
13.39% [25], Ansari et al., 12.4% [26], and Sah et al., 12.1% [17] from 
Nepal, Parasa et al., 15.03% from India [27], and Van der Heijden 
et al., 12.3% from Brazil [28]. Different prevalence rates of iMLSB 
have been reported in other studies; Mohapatra et al., 18.2% [29], 
Raut et al., 25.6% [30], Shrestha et al., 20.6% [31] from Nepal, and 
Lall et al., 20.30% [32] from India. Higher iMLSB prevalence of 45% 
from Germany [33] and 62% from the US [34] has also been reported. 
Constitutive clindamycin resistance (cMLSB) phenotype was found to 
be 19.50% in the present study, which is low as compared to another 
study [23,29,31,32]. Such disparity could be because of variation in 
a study period, group of patients, and geographical site. The present 
study demonstrated a higher prevalence of both iMLSB and cMLSB 
among MRSA as compared to MSSA. This finding is consistent with 
other reports [17,25,29,31,32]. However, Schreckenberge et al. [16], 
Levin et al. [35], and Marr et al. [36] reported a higher incidence 
of iMLSB among MSSA. In the present study, MRSA was dominant in 
male (31.2%) while MSSA was dominant in female (21.1%); a similar 
study was conducted by Raut et al. reported 52.3% and 64.3%, 
respectively [30]. In our study, MRSA was found to be dominant (47.7%) 
in the pus sample which is consistent with the reports of other authors, 
Raut et al. (49.2%) [30], Pandey et al. (28.73%) [37], and Shrestha et al. 
(82.6%) [31]. However, in the study by Thapa et al. [38], S. aureus was 
dominant in blood sample 44.60% while 23.40% was in pus.
This study demonstrated that overall rates of susceptibility pattern 
of S. aureus to the commonly used antibiotics were less than 65%, 
except clindamycin, amikacin, vancomycin, linezolid, and teicoplanin. 
A high proportion of isolates, 85.93% were resistant to penicillin. 
This result was expected as only a few strains of S. aureus do not 
produce beta-lactamases [26]. Ciprofloxacin being cheap and easily 
available antibiotics it has been widely used to treat against S. aureus. 
In this study, resistance rate of ciprofloxacin was 69.53%, which 
is comparatively higher than a report of Ansari et al., 63.7% [26]. 
Some other researchers found a resistance rate of ciprofloxacin to be 
32.73% by Sanjana et al. [39] and 11% by Baral et al. [40]. The rate of 
resistance of cotrimoxazole in our study was 41.41% which is similar to 
a study by Shrestha et al. [31]. Baral et al. found 64% rate of resistance 
to cotrimoxazole which is higher than in our study [40]. Similarly, 
gentamicin was 51.56% resistant in our study which is comparable to 
54.50% found by Mishra et al. [41]. Fortunately, the rate of resistance to 
amikacin is low at 11.71%. All the isolates (100%) in the present study 
were susceptible to vancomycin and teicoplanin, this report is consistent 
with other studies [25,26,39-41], this proves that glycopeptides should 
be used as empiric therapy for serious staphylococcal infections. 
Table 1: Susceptibility pattern against erythromycin and clindamycin among MRSA and MSSA isolates (n=525)
Isolates iMLSB (%) cMLSB (%) MS (%) MLSB sensitive (%) Total (%) p-value
MRSA 64 (12.19) 79 (14.80) 52 (9.90) 120 (22.86) 315 (60.00) p<0.001
MSSA 16 (3.05) 21 (4.00) 13 (2.48) 160 (30.48) 210 (40.00)
Total 80 (15.24) 100 (19.05) 65 (12.38) 280 (53.33) 525 (100.00)








No. % No. %
Aminoglycosides Amikacin 63 12.00 462 88.00
Gentamicin 268 51.56 257 48.95
β-lactams Amoxicillin/
clavulanic acid
315 60.00 210 40.00
Penicillin 450 85.71 75 14.29
Cefoxitin 309 58.86 216 41.14
Ceftriaxone 325 61.90 200 38.10
Cloxacillin 300 57.14 225 42.86
Piperacillin/
tazobactam
320 60.95 205 39.05
Glycopeptides Vancomycin 00 00.00 525 100.00
Teicoplanin 00 00.00 525 100.00
Lincosamides Clindamycin 178 33.90 347 66.10
Macrolides Erythromycin 247 47.05 278 52.95
Oxazolidinones Linezolid 00 00.00 525 100.00
Quinolones Ciprofloxacin 362 68.95 163 31.05
Sulfonamides Cotrimoxazole 216 41.14 309 58.86
Tetracyclines Tigecycline 289 55.05 236 44.95
Tetracycline 236 44.49 289 55.05
Fig. 3: Susceptibility pattern against erythromycin and 
clindamycin among Staphylococcus aureus isolates (n=525)
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Absolutely susceptibility of this drug in Nepal might be related to the 
low use of this agent due to its high cost [26]. Linezolid is another drug 
to have 100% susceptibility which is consistent with the report of Singh 
et al. [25] and Raut et al. [30].
CONCLUSION
In this study, cMLSB phenotype was predominant (19.05%) followed 
by iMLSB phenotype (15.25%) and then MS phenotype (12.38%). 
Inducible MLS B phenotypes, as well as cMLSB, are higher among 
MRSA. Clindamycin, which has outstanding bone and tissue penetration 
along with its ability to accumulate in an abscess, has become one of 
the beneficial antibiotics to treat S. aureus infection. Therefore, D-test 
should be performed routinely and the clinician should be enlightened 
regarding the likely failure of clindamycin therapy in infections caused 
by S. aureus harboring iMLSB resistance.
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